logo
  

Novartis Q2 Core Profit Rises In Constant Currencies Excl. Roche Investment Impacts

Novartis (NVS) reported second quarter core net income of $3.4 billion, down 8%, or down 1% constant currencies, as growth in core operating income was more than offset by the loss of Roche core income. Excluding the impact of Roche core income, core net income increased 8% in constant currencies. Core EPS was $1.56, down 6%, or up 1% in cc. Excluding the impact of Roche core income, core EPS increased 10% in cc.

Net income was $1.7 billion, a decline of 41%, or down 34% in constant currencies, mainly due to lower operating income. Excluding the impact of Roche income, net income declined 29% in cc. EPS was $0.77, down 40%, or a decline of 33% cc. Excluding the impact of Roche income, EPS declined 27% in cc.

Net sales were $12.8 billion, down 1%, or up 5% in constant currencies, driven by volume growth of 12 percentage points, price erosion of 4 percentage points and the negative impact from generic competition of 3 percentage points.

The company noted that the strategic review of Sandoz is on track; and it expects to provide an update, at the latest, by the end of 2022.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT